Context Therapeutics Investor Presentation Deck

Our Antibodies Display High Selectivity for CLDN6 Key Takeaways Benchmark (IMAB027) exhibits off-target binding to CLDN9 1st generation Context mAb (IM301, IM302) exhibit high CLDN6 selectivity 2nd generation Context mAb (data not shown) exhibit even greater CLDN6 selectivity than IM301 and IM302 • . Mean Fluorescence 150,000, 100,000- 50,000- 0+ -10 CLDN6 Benchmark -9 -8 -7 Log [MAb], M 19 Context Therapeutics Inc. - Sept. 2022 -6 CLDN9 150,000 100,000- 50,000- 0+ -10 CLDN3 CLDN4 IM 301 -9 -8 -7 Log [MAb], M 150,000 100,000- -6 50,000- 0+ CLDN6xCD3 Bispecific Antibody Program -10 IM 302 -9 -8 -7 Log [MAb], M -6 Benchmark = IMAB027 Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022

View entire presentation